Shilpa Gupta
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Otorhinolaryngology top 1%
Papers in
- Co-authors
- Kumudu Pathiraja (6 shared papers)Ravit Geva (5 shared papers)Laura Q.M. Chow (4 shared papers)Raanan Berger (5 shared papers)Jonathan D. Cheng (5 shared papers)Vassiliki Karantza (2 shared papers)Lajos Pusztai (2 shared papers)Laurence Buisseret (2 shared papers)
- Journals
- Annals of Oncology (19 papers)Journal of Clinical Oncology (13 papers)Clinical Genitourinary Cancer (13 papers)European Urology (11 papers)Journal of the National Comprehensive Cancer Network (8 papers)
- Partner nations
- United StatesIndiaUnited Kingdom
In The Last Decade
Shilpa Gupta
214 papers receiving 10.9k citations
Shilpa Gupta's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 5.1k
- Otorhinolaryngology 362
- Pulmonary and Respiratory Medicine 2.5k
- Surgery 2.7k
- Immunology 1.2k
Countries citing papers authored by Shilpa Gupta
This map shows the geographic impact of Shilpa Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shilpa Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shilpa Gupta more than expected).
Fields of papers citing papers by Shilpa Gupta
This network shows the impact of papers produced by Shilpa Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shilpa Gupta. The network helps show where Shilpa Gupta may publish in the future.
Co-authors
The 25 scholars most cited alongside Shilpa Gupta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 236 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Hit paper breakdown → | 2020 | 1331 |
| 2 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Hit paper breakdown → | 2016 | 1247 |
| 3 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Hit paper breakdown → | 2016 | 932 |
| 4 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Hit paper breakdown → | 2016 | 715 |
| 5 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 609 |
| 6 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 368 |
| 7 | Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2023 | 363 |
| 8 | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study Hit paper breakdown → | 2017 | 282 |
| 9 | 2021 | 234 | |
| 10 | 2020 | 233 | |
| 11 | Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2022 | 213 |
| 12 | 2015 | 201 | |
| 13 | Epidemiology, Screening, and Prevention of Bladder Cancer Hit paper breakdown → | 2022 | 200 |
| 14 | Prostate Cancer, Version 3.2024 Hit paper breakdown → | 2024 | 158 |
| 15 | 2011 | 148 | |
| 16 | 2021 | 141 | |
| 17 | 2022 | 135 | |
| 18 | 2018 | 109 | |
| 19 | 2020 | 107 | |
| 20 | 2021 | 105 |
About Shilpa Gupta
Shilpa Gupta is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 236 papers that have together received 11.1k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (81 papers), Prostate Cancer Treatment and Research (32 papers), Cancer Immunotherapy and Biomarkers (31 papers), Urinary and Genital Oncology Studies (27 papers), Renal cell carcinoma treatment (15 papers), COVID-19 and healthcare impacts (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cytokine Signaling Pathways and Interactions (7 papers). The work is most often cited by research in Oncology (5.1k citations), Otorhinolaryngology (362 citations), Pulmonary and Respiratory Medicine (2.5k citations), Surgery (2.7k citations) and Immunology (1.2k citations). Shilpa Gupta has collaborated with scholars based in United States, India and United Kingdom. Frequent co-authors include Kumudu Pathiraja, Ravit Geva, Laura Q.M. Chow, Raanan Berger, Jonathan D. Cheng, Vassiliki Karantza, Lajos Pusztai, Laurence Buisseret, Gursel Aktan and Elizabeth Claire Dees. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Genitourinary Cancer, European Urology and Journal of the National Comprehensive Cancer Network.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.